This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cerivastatin is the newest HMG-CoA reductase inhibitor to be introduced into clinical practice. It is metabolized via the cytochrome P450 3A4 as well as cytochrome P450 2C8 hepatic.¹ This dual metabolic elimination pathway is supposed to cause less drug-to-drug interaction. Therefore, cerivastatin is considered a safe and well-tolerated drug for the treatment of hypercholesterolemia. In clinical trials, its tolerability with regard to serum creatine kinase level and drug-induced myopathy was comparable to that of placebo.¹ However, there is a limited number of reports, including the case described by Garcia-Valdecasas-Campelo et al² in the March 26 issue of the ARCHIVES, which demonstrated muscle toxicity associated with cerivastatin treatment. All reports involved patients receiving cerivastatin in combination with fibrates or cyclosporine. Herein, we describe a patient who developed rhabdomyolysis after starting therapy with cerivastatin as the only lipid-lowering treatment.

Report of a Case

A 73-year-old woman was admitted to our department because of severe myalgia and . . . [Full Text of this Article]

Comment

RELATED ARTICLE

Acute Rhabdomyolysis Associated With Cerivastatin Therapy
E. Garcia-Valdecasas-Campelo, E. Gonzalez-Reimers, A. Lopez-Lirola, E. Rodriguez-Rodriguez, and F. Santolaria-Fernandez
Arch Intern Med. 2001;161(6):893.
EXTRACT | FULL TEXT